About US
Contact us
-
Sanofi hopes to make a splash with new meningitis vax initiativeAccording to a new survey, more than two-thirds of mothers have little to no knowledge of the CDC's recommendations for preventing meningococcalmeningitis. And if you're a meningitisvaccinemaker like2014/5/15
-
China speaks on GSK bribery charges, and the word isn't goodChina is coming down hard on GlaxoSmithKline's ($GSK) local operation. After a months-long bribery probe,Chinesepolice have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top2014/5/15
-
Akorn agrees to buy VersaPharmUS-based Akorn has entered into a definitive agreement to acquire VPI Holdings, the parent company of VersaPharm, for $440m in cash. The privately held developer and marketer of multi-source prescrip2014/5/14
-
Bayer's Kogenate FS gets FDA approval for routine prophylaxis in Hemophilia A patientsBayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication of its Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to preve2014/5/14
-
AbbVie seeks EMA approval for marketing interferon-free hepatitis C therapy in EUUS-based biopharmaceutical firm AbbVie has submitted marketing authorisation applications (MAAs) to the European Medicines Agency (EMA) seeking approval for its investigational, all-oral, interferon-f2014/5/13
-
GSK and Theravance announce European approval for chronic obstructive pulmonary disease drugGlaxoSmithKline (GSK) and Theravance have announced the European Commission's marketing approval for Anoro (umeclidinium/vilanterol) for the treatment of chronic obstructive pulmonary disease (COPD).2014/5/13
-
NIH Study Demonstrates that a New Cancer Immunotherapy Method could be Effective Against a Wide Range of CancersA new method for using immunotherapy to specifically attack tumour cells that have mutations unique to a patient’s cancer has been developed by scientists at the National Cancer Institute (NCI), part2014/5/12
-
Janssen submits sNDA to FDA for genotype 1 chronic hepatitis C drugJanssen Research & Development has submitted a supplemental new drug application (sNDA) to US Food and Drug Administration (FDA) for Olysio (simeprevir) for once-daily use in combination with sofo2014/5/12
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Jinhua2014 PhexTour（Pharma Excipients Technical Application National Tour Seminar) 2nd station--Jinhua, was successfully concluded on 15 April at Hemei Jinpan Hotel . More than 100 technical persons from 22014/5/12
-
FDA to review Merck’s biologics licence application for advanced melanoma productThe US Food and Drug Administration (FDA) has accepted Merck's biologics licence application for review of its MK-3475, an investigational anti-PD-1 antibody, for advanced melanoma. The investigation2014/5/9